Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis

Adding mepolizumab to standard treatment with inhaled corticosteroids and controller medications could decrease asthma exacerbations and use of long-term oral steroids in patients with severe disease and increased eosinophils; however, mepolizumab is costly and its cost effectiveness is unknown.

http://ift.tt/2fXPAge